New combo drug aims to ease pain after breast surgery

NCT ID NCT03011333

Completed Symptom relief Sponsor: Heron Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a drug called HTX-011, which combines two pain relievers (bupivacaine and meloxicam), given as a nerve block before breast augmentation surgery. The goal was to see if it reduces pain and the need for opioid painkillers after the operation. The trial involved 243 women and compared HTX-011 to standard pain relief and a placebo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HTX-011 (bupivacaine and meloxicam combination)
What this could lead to: If it works, this could provide a new way to manage pain after surgery, reducing the need for opioids.
What could go wrong: This is an early phase 2 trial with 243 participants, so results may not apply to everyone. The drug may not be more effective than existing options.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POSTOPERATIVE PAIN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Pain, Postoperative

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

POSTOPERATIVE PAIN

Contacts and locations

Show contact details

Locations

Study site

Pasadena, California, 91105, United States
Study site

Houston, Texas, 77027, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.